The activities of tigecycline and eight other agents were evaluated against 220 coryneform bacteria and 42 Listeria monocytogenes isolates. All strains were inhibited by tigecycline at 0.5 g/ml, except for 11 Corynebacterium striatum strains that were inhibited at 1 g/ml. Tigecycline shows good in vitro activity against coryneform bacteria and L. monocytogenes.
the Hospital Universitario Marqués de Valdecilla, Santander, Spain (n ϭ 172) or were provided from several centers in Spain (n ϭ 90) (see the acknowledgments for details). Microorganisms were identified according to the method of Funke et al. (3) , using API-CORYNE strips (BioMérieux, Marcy l'Étolie, France) and additional phenotypic tests when necessary. Sequencing of the 16S rRNA gene was performed when phenotypic traits were unable to provide a definitive identification. After identification, organisms were maintained in tryptic soy broth-10% glycerol at Ϫ80°C. They were subcultured twice on Columbia agar-5% sheep blood (Becton Dickinson) before susceptibility testing.
The MICs of tigecycline (Wyeth, Pearl River, NY), doxycycline (Sigma, Madrid, Spain), minocycline (Sigma), tetracycline (Sigma), vancomycin (Sigma), cefuroxime (Sigma), clindamycin (Sigma), gentamicin (Sigma), and levofloxacin (Aventis Pharma, Antony, France) were determined by microdilution using Mueller-Hinton broth with 3% laked horse blood according to the guidelines of the M45-A document from CLSI (2). Tigecycline, doxycycline, and clindamycin were tested in the range of 0.015 to 16 g/ml; all other compounds were tested in the range of 0.03 to 32 g/ml. A fresh solution of tigecycline prepared from reference powder was used every day that a batch of microdilution plates was used, until completion of the study. Staphylococcus aureus ATCC 29213 and Enterococcus faecalis ATCC 29212 were used as control strains for susceptibility testing assays. MICs for these two strains were within the accepted ranges indicated by the CLSI.
MIC 50 s, MIC 90 s, and MIC ranges of tigecycline and comparators against the tested strains are presented in Table 1 . The CLSI has defined clinical breakpoints for several agents against coryneform bacteria. These breakpoints are often adapted from those previously established for staphylococci. However, the CLSI, as well as other agencies or committees, have not yet defined breakpoints for tigecycline for coryneform bacteria or L. monocytogenes. As a reference, the breakpoint for susceptibility of staphylococci defined by the FDA is 0.5 g/ml.
All coryneform bacteria, except 11 out of 59 C. striatum isolates, were inhibited by 0.5 g/ml of tigecycline. These 11 C. striatum were inhibited at 1 g/ml of tigecycline. Although the CLSI recommends using blood-supplemented broth for testing coryneform bacteria, C. striatum (and other species commonly isolated from human samples, including C. amycolatum) is able to grow in nonsupplemented Mueller-Hinton broth (5) (6) (7) . MICs of tigecycline were tested against 33 out of the 59 C. striatum isolates included in this study for which the MICs of tigecycline were Ն0.125 g/ml: in 25 isolates, MICs of tigecycline were two to four times lower in plain Mueller-Hinton broth than in blood-supplemented Mueller-Hinton broth. In the absence of additional clinical information, it is not possible to determine the relevance of these differences. It could be possible that MICs of tigecycline for other nonfastidious corynebacteria are also lower in nonsupplemented MuellerHinton broth.
All L. monocytogenes strains were inhibited by tigecycline at 0.5 g/ml, with an MIC 90 of this compound of 0.125 g/ml, the same value presented in a recent report where 100 isolates were tested (1) .
Ninety-six to one hundred percent of isolates of C. amycolatum, C. jeikeium, C. minutissimum, C. pseudodiphtheriticum, C. xerosis, and L. monocytogenes were susceptible to tetracycline, but a significant number of strains of C. striatum (58%), R. equi (55%), A. haemolyticum (35%), and to a lesser extent C. urealyticum (12%) were not susceptible to this compound. Doxycycline and minocycline were also poorly active against C. striatum and some strains of C. urealyticum. MIC 90 s of tigecycline were lower than those of tetracycline, doxycycline, and minocycline for most of the tested species (being equal for the remaining ones), which indicates that, as already noted for other organisms, tigecycline maintains in vitro activity against corynebacteria for which tetracyclines are not active. In a previous study (4) on 21 isolates of Corynebacterium spp., the MIC 50 and MIC 90 of tigecycline were 0.06 and 0.125 g/ml, respectively, similar to those of minocycline and lower than the corresponding ones for doxycycline and tetracycline.
Few studies are available about the mechanisms of resistance of corynebacteria to tetracyclines. TetM is common in C. striatum isolates (10) of clinical origin, and tetAB genes have been identified in the 50-kb R-plasmid pTP10 from the clinical isolate C. striatum M82B (initially thought to be C. xerosis) (14) . TetA(Z) has also been identified as a tetracycline resistance determinant of plasmid pAG1 from the soil bacterium Corynebacterium glutamicum 22243 (15) , and the related Tet 33 on September 9, 2017 by guest http://aac.asm.org/ was recognized in plasmid pTET3 from C. glutamicum . Additional studies would be helpful for understanding the ability of tigecycline to escape the mechanisms of resistance to tetracyclines in the bacteria we have evaluated.
The activities of other antimicrobial agents against organisms included in this study are in agreement with previous reports (5-8, 12 ). All strains of corynebacteria and L. monocytogenes we studied were susceptible to vancomycin. All isolates of A. haemolyticum were susceptible to clindamycin, but for other species, the percentages of susceptibility to this agent were rather low: 0% (C. jeikeium), 5% (C. striatum), 10 to 13% (C. amycolatum, C. minutissimum, and R. equi), and 20 to 26% (C. xerosis, C. urealyticum, and C. pseudodiphtheriticum). Levofloxacin maintained good activity against A. haemolyticum and L. monocytogenes, but poor activity of this quinolone was observed against most species of Corynebacterium, as already published, which may be related to the presence of mutations in gyrA and the absence of topoisomerase IV (11) . Gentamicin was poorly active against multiresistant species such as C. jeikeium (only 8% of isolates were susceptible) and C. urealyticum (30% of isolates susceptible); 65% of C. amycolatum and 14% of C. striatum isolates were nonsusceptible to this aminoglycoside. Cefuroxime also poorly inhibited C. jeikeium, C. urealyticum, and L. monocytogenes.
In conclusion, tigecycline showed an excellent in vitro activity against coryneform bacteria, including several species of Corynebacterium, A. haemolyticum, and R. equi. This suggests that tigecycline may represent a reasonable therapeutic alternative for infections caused by these organisms. It is also active against many gram-negative bacteria (eventually present in mixed infections) not covered by anti-gram-positive drugs such as glycopeptides, which are often referred to in the literature as drugs of choice for these organisms. In addition, it may be considered as an alternative against multiresistant corynebacteria, for which the current options are rather limited. Tigecycline is also active in vitro against L. monocytogenes. Its clinical usefulness against this organism warrants further studies.
